For decades, the shingles vaccine has been recommended for one straightforward reason: to prevent a painful, blistering rash and the nerve pain that can linger long after. But a wave of new research is uncovering something unexpected — adults who get vaccinated against shingles appear to be less likely to develop dementia in the years that follow.
The findings, published in top journals including Nature and Nature Medicine, have prompted scientists to reconsider how routine adult vaccines might shape brain aging. Here is what the evidence actually shows, what remains uncertain, and how researchers think a vaccine for a skin condition could possibly protect the brain.
A Natural Experiment in Wales
The story begins with an unusual policy quirk. In September 2013, Wales began offering the live shingles vaccine (Zostavax) to adults — but only those who were 79 years old on the day the program started. People who had turned 80 the day before were permanently ineligible. This created a near-perfect natural experiment: two groups of older adults, nearly identical in age and health, separated only by which side of an arbitrary cutoff their birthday fell on.
A team led by Stanford researcher Pascal Geldsetzer analyzed the health records of more than 280,000 older Welsh adults using this cutoff. Their study, published in Nature in 2024, found that those eligible for the shingles vaccine were about 20 percent less likely to develop dementia over the next seven years compared with those just one week too old to qualify.
Because eligibility was determined by birthday rather than by patient choice, the design sidesteps a common pitfall of observational research — the “healthy vaccinee” problem, in which people who seek out vaccines also tend to live healthier lives. As an analysis in Nature noted, the finding is one of the strongest causal signals to date that vaccination itself, rather than the kind of person who gets vaccinated, may play a role.
A Newer Vaccine, a Larger Effect
Zostavax, the live vaccine used in Wales at the time, has since been replaced in most countries by Shingrix, a recombinant vaccine that is more effective at preventing shingles itself. According to the U.S. Centers for Disease Control and Prevention, Shingrix is roughly 97 percent effective at preventing shingles in adults aged 50 to 69 and 91 percent effective in adults 70 and older — with protection holding for at least seven years.
An Oxford team led by Maxime Taquet examined whether the newer vaccine carried any cognitive advantage. Drawing on electronic health records from more than 200,000 U.S. adults, the researchers compared people who received Shingrix with those who received Zostavax. Their analysis, published in Nature Medicine in 2024, found that recipients of Shingrix lived an estimated 164 additional days without a dementia diagnosis over a six-year follow-up — a measurably larger effect than that seen with the older vaccine.
An Adjuvant Worth Watching
Why might Shingrix outperform Zostavax in brain outcomes? One hypothesis points to AS01, the adjuvant — the immune-boosting ingredient — included in Shingrix. AS01 is also used in Arexvy, the respiratory syncytial virus (RSV) vaccine approved for older adults. Early observational data suggest Arexvy may produce a similar dementia-associated benefit, raising the possibility that the adjuvant itself, not the specific virus being targeted, is driving the effect. Mouse studies have hinted at neuroprotective signaling from AS01, though the mechanism is still being worked out.
How Could a Skin Virus Affect the Brain?
Shingles is caused by the reactivation of varicella-zoster virus (VZV), the same virus that causes chickenpox in childhood. After a chickenpox infection, VZV lies dormant in nerve cells, sometimes for decades, before flaring up later in life as shingles.
Researchers have long suspected that latent and reactivating herpesviruses, including VZV and herpes simplex, may contribute to neuroinflammation and amyloid buildup in the brain — both of which are linked to Alzheimer’s disease. By preventing reactivation, the shingles vaccine may indirectly reduce a chronic inflammatory trigger. The adjuvant hypothesis adds a parallel track: the vaccine may also “train” the aging immune system in ways that calm low-grade inflammation throughout the body, including in the brain.
Both pathways remain hypotheses. As neurology researchers have emphasized, the studies so far show association and timing, not biological proof.
What the Findings Do — and Don’t — Mean
The shingles-vaccine-dementia link is one of the most promising signals in recent neurodegeneration research, but several caveats matter:
- Not a treatment. No study has shown the vaccine reverses cognitive decline in people who already have dementia. The benefit, if real, appears to be preventive.
- Effect sizes vary. A 20 percent reduction over seven years, or about five extra months without a dementia diagnosis, is meaningful at a population level but modest for any individual.
- Randomized trials are still needed. Most evidence comes from observational data or natural experiments. Several randomized trials specifically testing vaccination strategies for dementia prevention are now being planned or underway.
- Other risk factors still matter. Blood pressure control, sleep, exercise, hearing health, diet, and social engagement all have stronger evidence behind them. Vaccination, if confirmed, would be one piece of a larger preventive strategy.
Who Is Eligible for Shingrix Today
The CDC currently recommends Shingrix for:
- Adults aged 50 and older, given as two doses separated by two to six months.
- Adults aged 19 and older who are immunocompromised because of disease or medical therapy.
- People who previously received Zostavax or had a past episode of shingles — they remain eligible and may benefit from the newer vaccine.
Common side effects include sore arm, fatigue, and short-lived flu-like symptoms after the second dose. Serious reactions are rare. Insurance coverage in the United States typically includes Shingrix under Medicare Part D and most commercial plans for eligible adults.
The Bigger Picture
Dementia affects an estimated 55 million people worldwide, according to the World Health Organization, with cases projected to nearly triple by 2050. There is still no medication that meaningfully reverses Alzheimer’s disease, and the most effective tools remain prevention-oriented — managing midlife blood pressure, treating hearing loss, staying physically and socially active, and protecting sleep.
If forthcoming trials confirm that the shingles vaccine, or its adjuvant, modestly lowers dementia risk, it would add a simple, scalable tool to that list — one that older adults are already encouraged to receive for an entirely different reason. The vaccine’s primary job is still to prevent shingles and the months of nerve pain that can follow. A possible bonus for brain health makes the case for staying up to date that much stronger.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.